YouTube video by Open Bionics

Ekso Bionics (Nasdaq: EKSO) announced a registered direct offering entered on October 28, 2025 to sell 769,490 shares of common stock at $4.81 per share in an at-the-market transaction under Nasdaq rules.The offering is expected to close on or about October 30, 2025, with gross proceeds of approximately $3.7 million before placement agent fees and other offering expenses. Lake Street Capital Markets is the exclusive placement agent.The company intends to use net proceeds for general corporate purposes, including research and development, selling, general and administrative costs, strategic initiatives and working capital. The shares are being offered under a Form S-3 shelf registration declared effective June 20, 2023.

Ekso Bionics (Nasdaq: EKSO) reported Q3 2025 results on Oct 28, 2025: revenue $4.2M (up 2% YoY, up 105% sequentially), gross margin 60.3% (up 680 bps YoY, driven by higher Enterprise Health sales and lower device cost), and net loss $1.4M (improved 31% YoY, $0.54 per share). Operating expenses declined across S&M, R&D and G&A mainly due to Employee Retention Credit benefits.The company had $2.7M cash at Sept 30, 2025 and announced it is exploring strategic transactions, which may include divestiture or acquisition and could require substantial issuance of company securities.

Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2025 and raised its full year guidance for the year

Ekso Bionics (NASDAQ:EKSO – Get Free Report) is expected to post its Q3 2025 results before the market opens on Monday, October 27th. Analysts expect Ekso Bionics to post earnings of ($0.99) per share and revenue of $4.1560 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for […]

Inspired by animal vision, the eye could become part of soft robots without any electronic components.

A tiny chip implanted into the eyes of people suffering vision loss from irreversible age-related...

A tiny chip implanted into the eyes of people suffering vision loss from irreversible age-related macular degeneration has restored central sight in a dazzling first.